Alluvi, formerly BI 4744, represents a promising breakthrough in obesity treatment. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates compelling efficacy in https://alluvi937397.bloggazza.com/profile